Therapeutic implications of osteoprotegerin
<p>Abstract</p> <p>Osteoprotegerin (OPG), a member of the tumor necrosis factor (TNF) receptor superfamily, contributes determinatively to the bone remodeling as well as to the pathogenetic mechanism of bone malignancies and disorders of mineral metabolism. There is additional evid...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-09-01
|
| Series: | Cancer Cell International |
| Online Access: | http://www.cancerci.com/content/9/1/26 |
| _version_ | 1818056604202827776 |
|---|---|
| author | Karalaki Maria Fili Sofia Schaller Bernhard |
| author_facet | Karalaki Maria Fili Sofia Schaller Bernhard |
| author_sort | Karalaki Maria |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Osteoprotegerin (OPG), a member of the tumor necrosis factor (TNF) receptor superfamily, contributes determinatively to the bone remodeling as well as to the pathogenetic mechanism of bone malignancies and disorders of mineral metabolism. There is additional evidence that OPG can promote cell survival by inhibiting TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. A number of recent <it>in vitro, in vivo</it> and clinical studies have defined the role of the RANK/RANKL/OPG pathway in skeletal and vascular diseases. These works were the milestone of the deep understanding of the mechanism of OPG. This review provides an overview of the potential innovative therapeutic strategies of OPG in metastatic breast and prostate carcinoma, multiple myeloma, postmenopausal osteoporosis, glucocorticoid-induced osteoporosis and rheumatoid arthritis. Special reference is given to the increasing evidence that RANKL and OPG may link the skeletal with the vascular system.</p> |
| first_indexed | 2024-12-10T12:31:29Z |
| format | Article |
| id | doaj.art-e8d09fbff51f49aaa753d9b24b047b32 |
| institution | Directory Open Access Journal |
| issn | 1475-2867 |
| language | English |
| last_indexed | 2024-12-10T12:31:29Z |
| publishDate | 2009-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj.art-e8d09fbff51f49aaa753d9b24b047b322022-12-22T01:48:48ZengBMCCancer Cell International1475-28672009-09-01912610.1186/1475-2867-9-26Therapeutic implications of osteoprotegerinKaralaki MariaFili SofiaSchaller Bernhard<p>Abstract</p> <p>Osteoprotegerin (OPG), a member of the tumor necrosis factor (TNF) receptor superfamily, contributes determinatively to the bone remodeling as well as to the pathogenetic mechanism of bone malignancies and disorders of mineral metabolism. There is additional evidence that OPG can promote cell survival by inhibiting TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. A number of recent <it>in vitro, in vivo</it> and clinical studies have defined the role of the RANK/RANKL/OPG pathway in skeletal and vascular diseases. These works were the milestone of the deep understanding of the mechanism of OPG. This review provides an overview of the potential innovative therapeutic strategies of OPG in metastatic breast and prostate carcinoma, multiple myeloma, postmenopausal osteoporosis, glucocorticoid-induced osteoporosis and rheumatoid arthritis. Special reference is given to the increasing evidence that RANKL and OPG may link the skeletal with the vascular system.</p>http://www.cancerci.com/content/9/1/26 |
| spellingShingle | Karalaki Maria Fili Sofia Schaller Bernhard Therapeutic implications of osteoprotegerin Cancer Cell International |
| title | Therapeutic implications of osteoprotegerin |
| title_full | Therapeutic implications of osteoprotegerin |
| title_fullStr | Therapeutic implications of osteoprotegerin |
| title_full_unstemmed | Therapeutic implications of osteoprotegerin |
| title_short | Therapeutic implications of osteoprotegerin |
| title_sort | therapeutic implications of osteoprotegerin |
| url | http://www.cancerci.com/content/9/1/26 |
| work_keys_str_mv | AT karalakimaria therapeuticimplicationsofosteoprotegerin AT filisofia therapeuticimplicationsofosteoprotegerin AT schallerbernhard therapeuticimplicationsofosteoprotegerin |